Company

Location

Amount (US$M)

Round

Details

Date

Total: $1,828.49M

Antengene Corp.

Shanghai

$120.00

Series B

$120 M series B led by Boyu Capital and Fountainvest, with participation from Summit, N.J.-based Celgene Corp., Wuxi Corporate Venture Fund and Taikang; previous investors Qiming Venture Partners and TF Capital also participated

1/2/19

Apic Bio Inc.

Cambridge, Mass.

$40.00

Series A

$40M series A led by Morningside Venture Investments Ltd.; existing investors The Alpha-1 Project (TAP) and A1ATD Investors LLC also participated along with new investor, the ALS Investment Fund

1/8/19

Apollomics Inc.

Foster City, Calif.

$100.00

Series B

Raised $100M in a series B financing led by CMB International, a subsidiary of China Merchants Bank, with participation from existing series A investor Orbimed Asia, and several new investors

1/7/19

Atriva Therapeutics GmbH

Tubingen, Germany

N/A

Series A

Atriva made the first closing in its ongoing series A financing round led by Meneldor and High-Tech Grunderfonds GmbH

1/4/19

Attune Pharmaceuticals Inc.

New York

$23.00

Series B

$23M series B round led by Venrock Healthcare Partners, and joined by new investor Lifesci Venture Partners, and existing backers RTW Investments, RA Capital, Boxer Capital and Tang Capital

1/24/19

Biond Biologics Ltd.

Misgav, Israel

$17.00

Series B

$17M series B financing led by Israel Biotech Fund and Harel Insurance & Finance Group, with participation of Celgene Corp., the Japanese-Israeli fund, SBI JI Innovation Fund and existing investors

1/9/19

Biontech AG 

Mainz, Germany

$91.00

N/A

Received €80M (US$90.8M) from Sanofi as part of an extension of an existing alliance to develop synthetic mRNA-based cancer immunotherapies

1/7/19

Black Diamond Therapeutics Inc.

Cambridge, Mass.

$85.00

Series B

$85M in a series B round co-led by New Enterprise Associates and RA Capital Management; new investors Nextech Invest, The Invus Group and Perceptive Advisors joined founding investor Versant Ventures in the round

1/11/19

Blue Water Vaccines Inc.

New York

$15.00

N/A

$15M financing of Blue Water for its flu vaccine program

1/14/19

Bridgebio Pharma LLC

Palo Alto, Calif.

$299.20

N/A

$299.2M round co-led by existing investors KKR and Viking Global Investors; other existing investors included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital and Hercules Capital; new investors Sequoia Capital and an unidentified blue-chip long-term investor also participated

1/24/19

Cabaletta Bio Inc.

Radnor, Pa.

$50.00

Series B

Closed a $50M series B financing from new investors, Deerfield Management Co., Boxer Capital of Tavistock Group, Redmile Group and Cormorant Capital with pro rata participation from founding investors including Adage Capital Management, an undisclosed leading public equity healthcare investor and 5AM Ventures

1/4/19

Connect Biopharmaceuticals Ltd.

Suzhou, China

$55.00

Series B

Secured $55M in a series B financing round led by Advantech Capital and backed by veteran investors such as Qiming Venture Partners, Northern Light Venture Capital and Cowin Venture; CEC Capital was the financial adviser for the financing

1/7/19

Dewpoint Therapeutics Inc.

Cambridge, Mass.

$60.00

Series A

$60M series A led by its founding investor, Polaris Partners; Samsung's Samsara Biocapital, 6 Dimensions Capital, Ecor1 Capital, Alexandria Venture Investments and Bayer AG's Leaps investment arm

1/31/19

Edigene Inc.

Beijing

$10.00

Series pre-B

$10M through a series pre-B financing led by Green Pine, with participation from existing investors, including series A lead investor IDG Capital, and series B lead investor Lilly Asia Ventures and other insiders

2/5/19

Exonate Ltd.

Cambridge, U.K.

$1.89

Series D

Closed fourth financing round, raising £1.5 million (US$1.89 M) which will be used to accelerate the development of lead product, an eye drop for the treatment of retinal neovascular diseases; it is on track to enter clinical trials in diabetic macular edema in 2020

1/4/19

Exscientia Ltd.

Oxford, U.K.

$26.00

Series B

$26M series B round from two new investors, Celgene Corp. and Hong Kong-based GT Healthcare Capital Partners, and including existing backer Evotec AG

1/8/19

F2G Ltd.

Manchester, U.K.

N/A

N/A

Raised funding from Morningside Venture Investments Ltd. after receiving a €24M (US$27.54M) loan from the European Investment Bank in November

1/8/19

Frequency Therapeutics Inc.

Woburn, Mass.

$42.00

Series B

Closed $42M series B financing led by Taiwania Capital Management and Axil Capital, a health care-focused venture fund spun out of Mizuho Securities

1/8/19

Hexaell Biotechnologies Ltd.

Shanghai

$7.30

Series A

Closed a series A round of RMB50M (US$7.3M) from Hyfinity Investments, a professional venture capital firm focused on biotech and med tech based in Beijing

1/4/19

Immunochina Pharmaceuticals Co. Ltd.

Beijing

$20.40

Series C

¥140M (US$20.4M) series C round led by a syndicate of Chinese and international investors, including Shougang Fund, Sherpa Venture Capital, Peter Thiel, Qingzhe Capital and China Resources Innovative Equity Investment Fund

1/23/19

Immusoft Corp.

Seattle

$20.00

Series B

Final closing of $20M oversubscribed series B financing was done; new and existing investors included Breakout Ventures, Alexandria Venture Investments, RBV Capital, DEFTA Partners and Mesa Verde Venture Partners

1/3/19

Juvenescence Ltd.

Douglas, Isle of Man

$46.00

Series B

$46M series B round, first tranche of $100M total; a second tranche is expected later this quarter

1/17/19

Keros Therapeutics Inc.

Lexington, Mass.

$23.00

Series B

$23M series B financing from existing investors Pontifax, Arkin Bio Ventures, Partners Innovation Fund and Medison Pharma; new investor Global Health Sciences Fund (GHS) also participated

1/8/19

Life Biosciences LLC

Boston

$50.00

Series B

$50M series B round from individuals, family trusts and other progessional investors

1/18/19

Lyndra Therapeutics Inc.

Watertown, Mass.

$55

Series B

$55M series B round from all previous investors in addition to Hopu Investments, Gilead Sciences Inc., Invus, the Bill & Melinda Gates Foundation and Orient Life also participating

1/30/19

Minervax ApS

Copenhagen

$5.00

N/A

€3.6M (US$4.1M) investment from the Novo Holdings Repair Impact Fund and an additional €800,000 (US$904,697) from Sunstone Capital

1/23/19

Nantcell Inc.

Los Angeles

$30.00

N/A

Celgene Corp., of Summit, N.J., has completed its crossover investment in Nantcell totaling $30M, bringing its overall investment in the company to $105M with a 2.8% ownership in the company

1/8/19

Napajen Pharma Inc.

Burlingame, Calif.

$12.40

Series C

$12.4M series C round led by existing investor INCJ Ltd. with participation by existing investor Mitsui & Co. Global Investment and new investor P&D Directions Inc.

1/9/19

Oculis SA

Lausanne, Switzerland

$15.70

Series B

CHF15.5M (US$15.7M) in an extension to its series B round

1/7/19

Pear Therapeutics Inc.

Boston

$64.00

Series C

Successfully closed a $64M series C financing led by Temasek, and joined by other existing investors including Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative, and Singapore-based EDBI; the round also saw participation from a group of new investors, including Blue Water Life Science Fund, LP., Trustbridge Partners and a major diversified hedge fund

1/4/19

Personal Genome Diagnostics Inc.

Baltimore

$75.00

Series B

$75M series B round led by Bristol-Myers Squibb and venture capital firm New Enterprise Associates

1/14/19

Promethera Biosciences SA

Mont-Saint-Guibert, Belgium

$11.30

Series D

€10M (US$11.3M) strategic investment from Itochu Corp., of Tokyo, the first lead investor in the company's series D round, which it expects to close in the first quarter; also raised €14.6M through a convertible bond issue to existing and new investors

1/4/19

Ribon Therapeutics Inc.

Lexington, Mass.

$65.00

Series B

$65M series B round led by the Novartis Venture Fund, with participation from new investors Johnson & Johnson Development Corp. and Celgene Corp.; existing investors, The Column Group, Deerfield Management, U.S./Canada Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital also participated

1/9/19

Sana Biotechnology Inc.

Seattle

N/A

Seed

Launched with undisclosed funding from Arch Venture Partners and F-Prime Capital

1/11/19

Schrodinger

New York

$85.00

N/A

$85M financing; the Bill and Melinda Gates Foundation Trust and Wuxi Apptec's corporate venture fund co-led the round, joined by Deerfield Management, Baron, Qiming Venture Partners and GV (formerly Google Ventures)

1/8/19

Sojournix Inc.

Waltham, Mass.

$44.00

Series C

$44M series C financing round from RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors

1/4/19

Stelexis Therapeutics LLC

New York

$43.00

Series A

$43M series A financing from Deerfield

1/8/19

Thousand Oaks Biopharmaceuticals Inc.

Thousand Oaks, Calif.

$45.00

Series A

$45M series A round led by New Alliance Capital and joined by ADDOR Capital, Tenyall & Sumin, Broadhi Capital, Qianrong, Ji Lin Ao Dong and Bluebay Capital; existing investor New Alliance Capital also participated

1/9/19

Tiburio Therapeutics Inc.

Cambridge, Mass.

$31.00

Series A

$31M series A financing from Cydan LLC's syndicate of life sciences investors, New Enterprise Associates, Longitude Capital, Lundbeckfonden Ventures and Alexandria Venture Investments

1/4/19

Vyome Therapeutics Inc.

Princeton, N.J.

$22.00

Series D

$22M financing led by Iron Pillar; existing investors Perceptive Advisors, Romulus Capital and Kalaari Capital also participated

1/3/19

Wren Therapeutics Ltd.

Cambridge, U.K.

$23.30

Series A

£18M (US$23.3M) series A round from an international syndicate led by the Baupost Group with participation from Lifeforce Capital and high net worth individuals

1/23/19


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

 

No Comments